

1 **Reliable CRISPR/Cas9 genome engineering in *Caenorhabditis elegans* using**
2 **a single efficient sgRNA and an easily selectable phenotype**

3
4
5
6 Sonia El Mouridi, Claire Lecroisey, Philippe Tardy, Marine Mercier,
7 Alice Leclercq-Blondel, Nora Zariohi, Thomas Boulin[§]

8
9
10 Institut NeuroMyoGène

11 Univ Lyon, Université Claude Bernard Lyon 1

12 CNRS UMR 5310, INSERM U1217

13 8 Rue Raphaël Dubois

14 69100, Villeurbanne, France

15
16
17 [§] Corresponding author: thomas.boulin@univ-lyon1.fr

18
19 Running title: *d10*-based genome engineering

20
21 3 Figures, 3 Tables, 2 Figure Supplements, 4 Supplementary Tables

22
23 Keywords: CRISPR/Cas9 genome engineering, *C. elegans*, mScarlet,
24 *dpy-10*, co-conversion
25

26 **ABSTRACT**

27 CRISPR/Cas9 genome engineering strategies allow the directed modification of the
28 *C. elegans* genome to introduce point mutations, generate knock-out mutants and
29 insert coding sequences for epitope or fluorescent tags. Three practical aspects
30 however complicate such experiments. First, the efficiency and specificity of single-
31 guide RNAs (sgRNA) cannot be reliably predicted. Second, the detection of animals
32 carrying genome edits can be challenging in the absence of clearly visible or
33 selectable phenotypes. Third, the sgRNA target site must be inactivated after editing
34 to avoid further double-strand break events. We describe here a strategy that
35 addresses these complications by transplanting the protospacer of a highly efficient
36 sgRNA into a gene of interest to render it amenable to genome engineering. This
37 sgRNA targeting the *dpy-10* gene generates genome edits at comparatively high
38 frequency. We demonstrate that the transplanted protospacer is cleaved at the same
39 time as the *dpy-10* gene. Our strategy generates scarless genome edits because it
40 no longer requires the introduction of mutations in endogenous sgRNA target sites.
41 Modified progeny can be easily identified in the F1 generation, which drastically
42 reduces the number of animals to be tested by PCR or phenotypic analysis. Using
43 this strategy, we reliably generated precise deletion mutants, transcriptional
44 reporters, and translational fusions with epitope tags and fluorescent reporter genes.
45 In particular, we report here the first use of the new red fluorescent protein mScarlet
46 in a multicellular organism. wrmScarlet, a *C. elegans*-optimized version, dramatically
47 surpassed TagRFP-T by showing an 8-fold increase in fluorescence in a direct
48 comparison.

49 Introduction

50 The pace of technical developments allowing the direct manipulation of genome
51 sequences has seen a marked acceleration in the last years with the emergence of
52 RNA-targeted nucleases derived from bacterial immune systems (Doudna and
53 Charpentier 2014; Zetsche *et al.* 2015). In particular, the binary system relying on the
54 *Streptococcus pyogenes* Cas9 endonuclease targeted by CRISPR (clustered,
55 regularly interspaced, short, palindromic repeat) RNAs has been successfully used to
56 generate point mutations, deletion or DNA insertions in an ever-growing number of
57 experimental systems. *S. pyogenes* CRISPR/Cas9 has been adapted early on in the
58 model nematode *C. elegans* (Friedland *et al.* 2013; Dickinson *et al.* 2013; Chen *et al.*
59 2013; Frøkjær-Jensen 2013; Dickinson and Goldstein 2016). Previously, heritable
60 genome engineering could only be achieved in *C. elegans* – with significant effort –
61 by remobilizing a *Drosophila Mos1* transposon, which could be inserted and excised
62 in the germline (Robert and Bessereau 2007; Frøkjær-Jensen *et al.* 2010).

63 Despite great promise and early success, day-to-day CRISPR experiments are often
64 not straightforward. Different factors might explain variability and inefficiency of
65 CRISPR/Cas9 genome engineering in *C. elegans*. One specific reason could be the
66 limited expression of heterologous genes in the germline due to dedicated co-
67 suppression mechanisms (Kelly and Fire 1998). One approach to circumvent this
68 problem has been to inject preassembled ribonucleoprotein (RNP) complexes of
69 SpCas9 and CRISPR RNAs (crRNA – tracrRNA duplexes) directly into the
70 germline (Cho *et al.* 2013; Paix *et al.* 2015). However, this approach is generally more
71 expensive and less practical than using DNA expression vectors.

72 Another general reason for CRISPR failure is that efficacy and specificity vary
73 tremendously between different single guide RNAs (sgRNA). Systematic analyses in
74 different systems have led to the prediction that protospacers terminating by a single
75 guanosine (GNGG) or ideally a double guanosine motif (GGNGG) are generally more
76 effective (Doench *et al.* 2014; Farboud and Meyer 2015). To estimate the prevalence
77 of such sites, we selected a set of 22 genes coding for two-pore domain potassium
78 channel subunits and collected the sequences of all sgRNA target sites in and close
79 to exons of these genes. On average, these 22 loci contained 138 ± 40 protospacers.
80 We found that $20 \pm 5\%$ of these matched the GNGG motif, and only $5 \pm 2\%$ matched
81 the GGNGG motif (Supplementary Table 1). Since, the proximity of an sgRNA to the
82 target site has a positive impact on the likelihood to generate gene edits (Paix *et al.*

83 2014), it is therefore likely that few or no high efficiency sgRNAs will be situated close
84 to a given target region.

85 One approach to compensate for low CRISPR/Cas9 activity has been to use
86 selection strategies to increase the number of tested progeny. Antibiotic and
87 phenotypic selection protocols have been adapted in *C. elegans* (Ward 2015;
88 Dickinson *et al.* 2015; Norris *et al.* 2015; Dickinson and Goldstein 2016; Schwartz
89 and Jorgensen 2016). They have the further advantage of reducing hands-on time
90 and facilitate the detection of successful genome editing events. When phenotypic or
91 antibiotic selection is not applicable, Co-CRISPR strategies can be used to increase
92 the likelihood of identifying individuals with genome edits. These co-conversion
93 approaches consist in injecting the sgRNA targeting a locus of interest together with
94 a second sgRNA that targets a “marker gene” (Kim *et al.* 2014; Arribere *et al.* 2014).
95 Progeny that carries a modification in the “marker” locus are then more likely to carry
96 edits in the locus of interest. However, since two distinct sgRNAs do not necessarily
97 cut with the same efficiency or in the same germ cell, effectiveness of traditional Co-
98 CRISPR co-conversion is variable and mostly indicates a successful injection and
99 expression of Cas9 and sgRNA.

100 While these major efforts have improved the efficiency of genome engineering in
101 *C. elegans*, it is still not at a level where it can be considered to work routinely and
102 easily in most labs. In addition, all available strategies require the protospacer
103 sequence to be disrupted once the edit is generated to prevent further CRISPR/Cas9
104 cutting/activity. This almost always requires the introduction of point mutations in the
105 protospacer adjacent motif (PAM) or in multiple bases of the protospacer. The
106 consequences of such mutations in introns and up- or downstream regulatory regions
107 are difficult, if not impossible to predict. Similarly, silent mutations in exons can have
108 unfavorable effects due to codon usage bias. Therefore, it would be ideal if genome
109 edits, in particular insertions or point mutations, could be generated without
110 modification of the surrounding original genomic sequence.

111 Finally, since CRISPR/Cas9 guide RNAs are short 19-20 bp long sequences, there
112 are often multiple closely matching sites (i.e. differing only by a few base pairs) in the
113 genome that could be targeted, albeit at lower frequency. While algorithms have
114 been developed to easily predict such potential off-target sites (Hsu *et al.* 2013;
115 Doench *et al.* 2016), the prevalence of undesired CRISPR events has not been

El Mouridi *et al.* – *d10*-based genome engineering

116 systematically analyzed in *C. elegans* and would require *ad hoc* experiments for each
117 sgRNA.

118 We describe here a two-step strategy for reliable and scarless modification of the
119 *C. elegans* genome using a single guide RNA that facilitates the detection of genome
120 engineering events based on an easily selectable phenotype. Indeed, we reasoned
121 that it should be possible to circumvent many practical hurdles described above if we
122 transplanted the protospacer for a highly-efficient sgRNA into a genomic locus of
123 interest to create an “entry strain” that would be more amenable to genome
124 engineering. Specifically, we inserted a protospacer and PAM from the *dpy-10*
125 gene (Arribere *et al.* 2014) – further referred to as the “*d10* site” or “*d10* sequence” –
126 close to the targeted genomic region. In this “*d10*-entry strain”, we could then induce
127 double-strand breaks at both the transplanted *d10* site and the endogenous *dpy-10*
128 locus using a single sgRNA. We demonstrated that the *d10* site and the *dpy-10* locus
129 were efficiently cut within the same nucleus. Finally, we found that co-conversion
130 events (insertions of fluorescent reporter genes and epitope tags) occurred on
131 average in 8 % (i.e. 1 in 12 animals) of F1 progeny that also carried mutations in the
132 marker gene *dpy-10*, revealing a high incidence of co-conversion events. Since this
133 co-conversion step no longer relied on an endogenous protospacer from the targeted
134 locus, we did not need to introduce mutations in PAM or protospacer sequences and
135 could generate perfectly accurate and scarless genome edits. Although our strategy
136 is especially suited to insert sequences into the genome, we could also obtain large,
137 precisely targeted gene deletions.

138

139 **Materials and Methods**

140 ***Strains generated in this study***

141 N2 Bristol was used as a wild-type starting strain for transgenic lines generated in
142 this study. Worms were raised at 20°C on nematode growth medium and fed
143 *Escherichia coli* OP50. Worms were grown at 25°C after injection. Supplementary
144 Table 2 provides a comprehensive list of the strains constructed for this study.

145 ***Molecular Biology***

146 Single guide RNA expression vectors (see Supplementary Methods) and plasmid
147 repair templates were constructed using standard molecular biology techniques and
148 Gibson assembly (Gibson 2011). They were systematically validated by Sanger
149 sequencing before injection. Supplementary Table 3 and 4 respectively list the
150 oligonucleotides and vectors used in this study. The Cas9-expression vector pDD162
151 was obtained from Addgene (Dickinson *et al.* 2013). Vectors generated for this study
152 are available upon request.

153 ***DNA preparation and microinjection***

154 The pDD162, pMD8 and pPT53 plasmids were purified using the Qiagen EndoFree
155 Plasmid Mega Kit (Qiagen). All other vectors were prepared using Invitrogen
156 PureLink™ HQ Mini Plasmid Purification Kit (ThermoFisher Scientific). Single-strand
157 DNA repair templates were synthesized and PAGE-purified by Integrated DNA
158 Technologies (IDT). Except specified otherwise, plasmid vectors and ssDNA were
159 diluted in water and injected at a final concentration of 50 ng/μL; co-injection markers
160 were injected at 5 ng/μL. DNA mixes were injected into a single gonad of one day-old
161 adult hermaphrodites raised at 20°C. They were then cloned onto individual plates
162 after overnight incubation at 25°C.

163 ***PCR screening***

164 PCR DNA amplification was performed on crude worm extracts. In brief, worms were
165 collected in ice-cold 1X M9 buffer, and 5 μL of packed worms were lysed by freeze
166 thaw lysis in 14 μL of Worm Lysis Buffer (50 mM KCl, 10 mM Tris-HCl (pH = 8.3),
167 2.5 mM MgCl₂, 0.45% Nonidet P-40, 0.45% Tween 20, 0.01% (w/v) Gelatin), to which
168 1 μL of proteinase K was added (1 mg/mL final concentration). After freezing at -
169 80°C, lysates were incubated for 1 hour at 65°C, and proteinase K was inactivated by
170 further incubation at 95°C for 20 minutes.

171 High-fidelity DNA polymerases (Q5® High-Fidelity DNA Polymerase, New England
172 Biolabs; Phusion High-Fidelity PCR Kit, Thermo Fisher Scientific) were used for PCR
173 amplification to maximize the chances of recovery of desired modifications. Indeed,
174 when we generated the *TagRFP-T::twk-18* knock-in strain, we initially screened 77
175 F1 clones using a low fidelity DNA Polymerase (Taq'Ozyme, Ozyme) and found no
176 edits. When we immediately rescreened the same worm lysates with a more
177 processive, high-fidelity DNA polymerase (Phusion, ThermoFisher Scientific) we
178 identified 5 positive clones. PCR primers used for this study are listed in
179 Supplementary Table 3.

180 **Generation of sgRNA expression vector by single strand DNA isothermal** 181 **ligation**

182 All sgRNA expression vectors were built using the novel pPT2 vector (see below and
183 Supplementary Methods). In brief, pPT2 was linearized by PmeI/SexAI double
184 digestion. The protospacer sequence was then inserted by isothermal ligation using a
185 single-strand oligonucleotide containing the protospacer sequence flanked by 20 bp-
186 long homology arms corresponding to the sequences upstream of PmeI and
187 downstream of SexAI. If it was not already present in the sequence, a guanine
188 residue was manually added 5' to the protospacer sequence to optimize U6 promoter
189 activity. A unique identifier was given to each sgRNA using the following
190 nomenclature: CRpXYn, where "CR" stands for "CRISPR/Cas9 recognition site" and
191 pXYn is the name of the corresponding sgRNA-expression plasmid.

192 **Codon-optimization of mScarlet**

193 wrmScarlet was generated by gene synthesis (Gblock, IDT) based on the mScarlet
194 sequence (Genbank KY021423; (Bindels *et al.* 2017); Figure 3 Supplement 1).
195 Codon-optimization was performed using the "*C. elegans* codon adapter" service
196 (Redemann *et al.* 2011) with the following parameters: "0 introns", "optimize for weak
197 mRNA structure at ribosome binding site", and "avoid splice sites in coding region".
198 The Gblock fragment library was combined by isothermal ligation with left and right
199 homology regions flanking the *d10* sequence in *twk-18(bln213)* to generate the repair
200 template pSEM87. The wrmScarlet cDNA sequence is available upon request.

201 **Microscopy and fluorescence quantification**

202 Freely-moving worms were observed on NGM plates using an AZ100 microscope
203 (Nikon) equipped with a Flash 4.0 CMOS camera (Hamamatsu Photonics).

El Mouridi *et al.* – *d10*-based genome engineering

204 Confocal imaging was performed using a Nikon Eclipse Ti inverted microscope
205 equipped with a CSUX1-A1 spinning-disk scan head (Yokogawa) and an Evolve
206 EMCCD camera (Photometrics). Worms were imaged on 2% fresh agar pads
207 mounted in M9 solution containing 50 mM NaN₃.

208 Comparison of wrmScarlet and TagRFP-T fluorescence was performed as follows:
209 (1) confocal stacks of the head region were acquired for TagRFP-T and wrmScarlet
210 knock-in strains on the same day, using identical settings, and NaN₃ immobilization;
211 (2) the same number of confocal slices was selected from each stack; (3) stacks
212 were projected by summing fluorescence at each pixel position in the stack; (4) total
213 fluorescence was measured in areas of identical size and position relative to the
214 anterior tip of the worm and pharynx; (5) total fluorescence was corrected by
215 subtracting equipment noise, i.e. fluorescence measured in an area of the same size
216 outside of the sample.

217 ***Data and reagent availability***

218 All *C. elegans* strains and plasmids described in this study are available upon
219 request.

220

221 **Results**

222 **Generation of *d10*-entry strains as a starting point for robust and precise gene** 223 **modification**

224 The starting point of our strategy consists in the insertion of the *d10* sequence (i.e.
225 *dpy-10* protospacer + PAM) into the locus of interest (Figure 1A). First, we targeted
226 three positions in two genes coding for two-pore domain potassium channel subunits:
227 (1) the ATG start site of *sup-9*, (2) the ATG of the *egl-23b* isoform and (3) the
228 common stop codon of all *egl-23* isoforms (Figure 1A). Next, we predicted all
229 possible sgRNA sequences within a 50-base window around these positions, and
230 selected sgRNAs close to the ATG or stop codons. Using multiple sgRNAs increases
231 the chances of finding at least one sgRNA that cuts efficiently enough to insert the
232 *d10* site at the desired location. We then defined the portion of the gene to be
233 replaced by the *d10* site, based on the positions of the most upstream and most
234 downstream PAM sequences. Finally, we designed a single-strand oligonucleotide
235 sequence (ssON) containing the *d10* sequence flanked by up- and downstream
236 homology regions of approximately 50 bases (Figure 1A). This ssON could serve as
237 a repair template with all selected sgRNAs since it did not contain their protospacer
238 or PAM sequences.

239 Next, we built the necessary sgRNA expression constructs using a novel vector and
240 assembly strategy. This vector (pPT2) is composed of an RNA Polymerase III U6
241 promoter from *K09B11.12* (Friedland *et al.* 2013; Katic *et al.* 2015) followed by two
242 restriction sites (PmeI and SexAI), followed by the sgRNA portion corresponding to
243 the CRISPR tracrRNA and 3' UTR of *K09B11.12*. This vector was linearized by
244 restriction digest with PmeI and SexAI, and the crRNA sequence was incorporated
245 by isothermal ligation (Gibson assembly (Gibson 2011)) using a single single-strand
246 DNA oligonucleotide (see Materials and Methods and Supplementary Methods).
247 These sgRNA expression vectors were systematically validated using Sanger
248 sequencing.

249 Since it is not possible to predict the efficiency of an sgRNA *a priori*, we reasoned
250 that we could increase the likelihood of finding a *d10* insertion at the locus of interest
251 by using a moderately efficient Co-CRISPR. We chose a previously described
252 reagent combination that introduces a mutation in the two-pore domain potassium
253 channel *unc-58* and replicates the L428F amino acid change found in the *unc-*
254 *58(e665)* reference allele (Arribere *et al.* 2014). *unc-58(e665)* produces a dominant

El Mouridi *et al.* – *d10*-based genome engineering

255 and easily detectable phenotype. Worms have a straight body posture and are
256 essentially unable to move on solid NGM medium throughout their post-embryonic
257 development (Figure 1B). However, they are viable and fertile. *unc-58(e665)*-like
258 progeny can be detected two to three days post-injection and individual F1 worms
259 can be cloned right away to ensure that independent events are selected.

260 To generate *d10*-entry strains for *sup-9* and *egl-23*, we injected wild-type N2 worms
261 with a mix of plasmid DNA and ssON repair templates (Figure 1B). In each case the
262 mix was composed of (i) a Cas9 expression vector (pDD162), (ii) the sgRNA
263 expression vector targeting *unc-58* (pPT53), (iii) one gene-specific sgRNA
264 expression vector, (iv) the ssON to introduce the *e665* mutation AF-JA-76(Arribere *et*
265 *al.* 2014), and (v) the ssON required to introduce the *d10* site (Figure 1A,
266 Supplementary Table 3). After three to four days, we cloned Unc-58-marked F1
267 worms to single plates. We then detected the presence of the *d10* site in the F2
268 population by PCR amplification and restriction digest. The *d10* sequence contains
269 sites for three restriction enzymes (BamI, BsrBI, and BssSI) that can be used for
270 restriction fragment length polymorphism analysis (RFLP) (Figure 1C). In each case,
271 we designed a PCR primer pair that produced a fragment of 500 to 600 bp, centered
272 on the *d10* site. In this way, we were able to generate multiple independent *d10*-entry
273 strains for each of the targeted loci (Table 1 and Supplementary Table 2). In each
274 case, we selected homozygous clones for the *d10* insertion that lacked the *unc-58*
275 gain-of-function mutation, and validated them by Sanger sequencing around the *d10*
276 sites.

277 Next we targeted the two-pore domain potassium channel subunit *twk-18* (Figure
278 1Ad). In this experiment, only one of 41 injected P0 worms gave a single Unc-58
279 worm (Table 1). Since this marked F1 worm did not incorporate the *d10* site in
280 *twk-18*, we decided to screen its unmarked siblings. Doing so, we found 7
281 independent insertion events out of 93 tested clones. Similarly, we found 3 additional
282 *d10* insertion events in 14 unmarked siblings of the *sup-9* experiment, and 6
283 additional *d10* insertions in 108 unmarked siblings of the experiment targeting the
284 ATG of the *egl-23b* splice variant (Table 1).

285 In conclusion, screening for Unc-58-marked F1 progeny allowed us to rapidly identify
286 P0 individuals for which the injection was successful and CRISPR/Cas9 activity was
287 present in the germline. Cloning Unc-58 worms at the F1 generation ensured that we
288 selected independent edits and decreased the number of animals to clone and

289 analyze by PCR. In three cases, we also found *d10* protospacer insertions in non-
290 marked siblings, although at lower frequencies than in Unc-58-marked F1 progeny. In
291 total we successfully targeted 5 different sites in the genome using this protocol
292 (Supplementary Table 2).

293

294 **Efficient and specific cutting of transplanted *d10* sites**

295 Different laboratories have independently reported that the sgRNA targeting the *d10*
296 site is among the most efficient ones currently known (I. Katic, M. Boxem, C. Gally,
297 J.-L. Bessereau, personal communication). The reasons for this high efficacy are
298 unclear. For example, the site matches the GNGG motif and not GGNGG (Farboud
299 and Meyer 2015). A more favorable chromatin organization or the sequence of the
300 *dpy-10* locus itself might explain high CRISPR activity in this gene. Since we
301 transplanted only the protospacer and PAM sequences of the *d10* site, we decided to
302 estimate the frequency of cuts in transplanted *d10* sites before attempting to
303 engineer these loci by homologous recombination.

304 DNA double-strand breaks can be repaired by homologous recombination using the
305 sister chromatid to restore a wild-type sequence or by non-homologous end joining
306 (NHEJ), which results in small indels close to the cut site. We reasoned that we could
307 therefore estimate the double-strand break frequency by looking for the destruction of
308 the restriction sites present in and around the -3/-4 position relative to the NGG, i.e.
309 the Cas9 cut site (Figure 1C). Note that only catastrophic events that result in
310 sufficiently modified *d10* sites that could no longer be targeted by the Cas9/*d10*-
311 sgRNA duplex would be detected in this way. This experiment therefore
312 underestimates the double-strand break frequency since precise repair events using
313 the sister chromatid would not be detected.

314 We selected four *d10*-entry strains on three different chromosomes (*tag-68 I*, *egl-23*
315 *IV*, *twk-18 X* and *unc-58 X*). Each strain was injected with a DNA mixture containing
316 (i) a Cas9 expression vector (pDD162), (ii) an sgRNA expression vector targeting
317 *dpy-10* (pMD8), and (iii) a ssON to introduce the *cn64* mutation (AF-ZF-827) in *dpy-*
318 *10* (Arribere *et al.* 2014). Next, we singled F1 progeny showing a Dpy-10 phenotype,
319 i.e. Rol (*cn64/+*), Dpy (-/-) or DpyRol (*cn64/-*) (Levy *et al.* 1993; Arribere *et al.* 2014).
320 Finally, we tested all clones that segregated the Dpy-10 phenotype in their progeny
321 and observed the loss of the BanI site in 14 to 26 % of them (Table 2). Since BanI is
322 located 5' to the cut site (Figure 1C), we tested the remaining BanI-positive clones

323 (i.e. lacking mutations in *BanI*) with *BsrBI* and *BssSI*. This lead us to identify
324 additional events, likely affecting the bases closest to the -3/-4 cut site. In total, we
325 found that between 33 and 52% of *Dpy-10*-marked F1 worms had lost at least one
326 restriction site, which demonstrates that heterologous *d10* sites can be cut at high
327 frequency and are present in Co-CRISPR-marked F1 progeny.

328 Bioinformatic analysis predicts a single, low scoring, off-target site for the *d10*
329 sgRNA, situated in the uncharacterized gene *R12E2.15* (Figure 1D). We investigated
330 potential off-target cutting of the *d10* sgRNA by analyzing the *R12E2.15* locus in 32
331 independent F1 worms that segregated the *Dpy-10* phenotypes. None of these 32
332 lines showed scars around the potential off-target cut site of the *d10* sgRNA.

333 Given the high correlation between worms displaying *Dpy-10* phenotypes and
334 double-strand break events in the transplanted *d10*-site, and given the high
335 selectivity of the *d10* sgRNA for the endogenous and transplanted sites, we chose to
336 focus only on *Dpy-10*-marked Co-CRISPR individuals in our co-conversion
337 experiments.

338

339 **Generation of multiple knock-in lines using a single *d10*-entry strain**

340 As a proof of principle for our strategy, we targeted the *twk-18* locus. TWK-18 is one
341 of 47 two-pore domain potassium channels in the *C. elegans* genome. Its expression
342 pattern and localization in body wall muscle cells has been reported previously
343 (Kunkel *et al.* 2000). We decided to generate two N-terminal fusions (1) with the red
344 fluorescent protein TagRFP-T (Shaner *et al.* 2008) and (2) with the blue fluorescent
345 protein TagBFP (Chai *et al.* 2012). As a repair template, we constructed two vectors
346 with left and right homology regions of 2073 and 1993 base pairs (Figure 2A). We
347 injected each repair template separately into the *twk-18 d10*-entry strain (JIP1143)
348 with (i) a Cas9 expression vector (pDD162), (ii) the sgRNA expression vector
349 targeting *dpy-10* (pMD8), (iii) the ssON to introduce the *cn64* mutation in *dpy-10* (AF-
350 ZF-827) and (iv) the fluorescent reporter pCFJ90 as a co-injection marker to identify
351 transgenic animals based on mCherry fluorescence in the pharynx (Figure 2B). We
352 selected 77 (TagBFP) and 98 (TagRFP-T) *Dpy-10*-marked F1 progeny. Finally, we
353 used PCR screening to identify 5 and 6 clones respectively, which had integrated the
354 TagRFP-T and TagBFP sequences in the *twk-18* locus, corresponding to a
355 recombination frequency of 6% of *Dpy-10*-marked F1 progeny (Table 3).

356 When we prepared these knock-in lines for observation by confocal fluorescence
357 microscopy, we noted that TWK-18-TagBFP had a very reproducible subcellular
358 distribution at the exterior surface of body wall muscle cells (Figure 3B). The highly
359 repetitive grid-like pattern was very different from the one reported previously since it
360 appeared to show strong GFP signal in the endoplasmic reticulum (Kunkel *et al.*
361 2000). This intracellular localization was not consistent with the electrophysiological
362 effect of TWK-18 gain-of-function mutants, in which TWK-18 most likely exerts its
363 hyperpolarizing role at the plasma membrane. We believe these differences probably
364 resulted from a strong over-expression of TWK-18 in this study compared to our
365 knock-in strain, highlighting the importance of physiological expression levels when
366 observing the distribution of cell surface-targeted channels and receptors (Gendrel *et al.*
367 2009). When comparing the TagRFP-T and TagBFP knock-in strains, we noticed
368 a marked difference in brightness but also in the apparent resolution (Figure 3B). The
369 overall pattern of TagRFP-T was similar to TagBFP but the longer emission
370 wavelength of TagRFP-T (emission maximum, 584 nm) did not afford the same
371 resolution as the much shorter emission wavelength of TagBFP (emission maximum,
372 457 nm). This is in part explained by the fact that resolution is proportional to the
373 emission wavelength, making TagBFP an interesting alternative to increase imaging
374 resolution without changing imaging hardware.

375 Next, we targeted three additional loci on different chromosomes (*sup-9 II*, *twk-40 III*,
376 and *egl-23 IV*) and generated seven different edits with a variety of insert types
377 (TagRFP-T, TagRFP-T::ZF1, SL2::TagRFP-T and TagBFP) (Table 3 and
378 Supplementary Table 2). We found that we could reliably edit these different loci.
379 Indeed, edit frequencies in Dpy-10-marked F1 worms ranged from 3% to 19%
380 (average 8 %). Taken together, these experiments demonstrate that it is possible to
381 take advantage of the high CRISPR activity of the *d10* sgRNA to robustly engineer
382 the genome of *C. elegans*. This strategy significantly reduces hands-on work by
383 focusing only on the animals that most likely carry genome edits. It generates
384 scarless edits since it does not require the introduction of mutations in endogenous
385 protospacer sequences.

386

387 **wrmScarlet, a brighter red fluorescent protein**

388 The development of improved blue (TagBFP, (Chai *et al.* 2012)), cyan (mTurquoise2,
389 (Goedhart *et al.* 2012)), green (mNeonGreen, (Shaner *et al.* 2013)), and red

390 fluorescent proteins (TagRFP-T, (Shaner *et al.* 2008)) has greatly increased our
391 capacity to detect proteins expressed at physiological levels. However, the properties
392 of these new fluorophores are generally characterized in bacteria or cell culture
393 systems, and are not always retained in *C. elegans* cells or in specific subcellular
394 compartments (Heppert *et al.* 2016).

395 In an effort to improve the detection of fusion proteins *in vivo*, we have investigated
396 the behavior of the recently described red fluorescent protein mScarlet (Bindels *et al.*
397 2017). mScarlet has currently the highest reported brightness, quantum yield and
398 fluorescence lifetime of any red fluorescent protein. We synthesized a *C. elegans*
399 codon-optimized cDNA (Redemann *et al.* 2011) of mScarlet, which we named
400 wrmScarlet (Figure 3 Supplement 1). We combined this cDNA with homology arms
401 flanking the *d10* site in *twk-18* to generate a *wrmScarlet::twk-18* repair plasmid
402 (pSEM87, Figure 2A, and Figure 3 Supplement 1). Following the same strategy as
403 before, we injected 29 P0 worms (*twk-18 d10*-entry strain, JIP1440) with an injection
404 mix containing (i) pDD162 (Cas9), (ii) the ssON to introduce the *cn64* mutation in
405 *dpy-10* (AF-ZF-827), (iii) the sgRNA expression vector targeting *dpy-10* (pMD8), and
406 (iv) *wrmScarlet::twk-18* repair plasmid (pSEM87). Out of 29 injected P0 worms, 11
407 produced Dpy-10 F1 progeny. In total, we analyzed 123 Dpy-10-marked F1 worms
408 that segregated Dpy-10 progeny and found 6 clones incorporating the wrmScarlet
409 sequence (Table 3).

410 While undetectable by eye, specific fluorescence can be observed on NGM plates in
411 *TagRFP-T::twk-18* worms with a macroscope (Nikon AZ100) coupled to a CMOS
412 camera (Flash 4, Hamamatsu Photonics). Using the same macroscope, acquisition
413 parameters and filter sets, wrmScarlet-TWK-18 was significantly brighter than the
414 TagRFP-T fusion, so much so that it became visible to the naked eye (Figure 3A).
415 We next compared the subcellular distribution and brightness of these two
416 translational fusions using spinning disk confocal imaging. Both protein fusions had
417 grossly identical distribution patterns (Figure 3B). However, the wrmScarlet fusion
418 was approximately eight times brighter than the TagRFT-T fusion in this assay
419 (Figure 3C). In fact, the distribution of the wrmScarlet::TWK-18 fusion protein
420 appeared more uniform than TagRFP-T::TWK-18, possibly due to the increased
421 fluorescent signal, which compensated for the reduced resolution when compared to
422 TagBFP (Figure 3B). These properties make wrmScarlet a very convincing

423 replacement for TagRFP-T and should greatly facilitate the detection of protein
424 fusions expressed at low, physiological expression levels.

425

426 **Generation of an epitope-tagged knock-in using a long single-strand** 427 **oligonucleotide**

428 For short edits, single-strand DNA oligonucleotides can be very efficient repair
429 templates (Zhao *et al.* 2014; Arribere *et al.* 2014; Katic *et al.* 2015). We tested if a
430 large ssON could be used as a repair template to integrate two repeats of the myc-
431 tag sequence into the *egl-23* locus (Figure 2 Supplement 1). We synthesized a 182
432 nucleotide-long ssDNA fragment containing part of last exon of *egl-23* to restore the
433 full-length C terminal sequence, followed by 75 nucleotides encoding two myc tag
434 sequences, and the original stop codon and 3' UTR region of the *egl-23* gene
435 (Supplementary Table 3). In theory, each strand could serve as a template for
436 recombination, but we selected the strand complementary to the sgRNA following the
437 observations of (Katic *et al.* 2015). We injected 30 P0 worms (JIP1150) with a DNA
438 mixture containing (i) a Cas9 expression vector (pDD162), (ii) the expression vector
439 for the *d10* sgRNA (pMD8), (iii) the ssON that introduces the *cn64* mutation in *dpy-10*
440 (AF-ZF-827), (iv) ssON containing the 2xMyc tag sequence (oSEM158) and (v)
441 pCFJ90 as a co-injection marker to identify transgenic animals based on mCherry
442 fluorescence in the pharynx. We selected 67 Dpy-10-marked F1 progeny and among
443 these, 9 carried the 2xMyc tag. This 14% edit frequency was comparable, yet slightly
444 higher than the average efficiency of longer inserts using double-strand DNA repair
445 templates (Table 3).

446 The high edit efficiency observed in this experiment shows that our strategy is very
447 effective to tag proteins of interest for immunohistochemical or protein biochemistry
448 experiments. Generating this epitope-tagged strain required less than two weeks,
449 with no additional cloning steps and could be repeated easily to integrate a variety of
450 epitope tags, opening the way for different downstream applications.

451

452 **Generation of a large, targeted deletion using a *d10*-entry strain**

453 One starting point for many CRISPR experiments is the desire to engineer loss-of-
454 function mutations in a gene of interest. Previously, researchers relied on random
455 mutagenesis with chemical mutagens or ionizing radiation followed by fastidious
456 screening and extensive backcrossing to wild-type strains to eliminate background

El Mouridi *et al.* – *d10*-based genome engineering

457 mutations (Boulin and Hobert 2012). CRISPR/Cas9 engineering offers the possibility
458 to generate gene deletions with minimal background mutations. A simple approach
459 relies on the repair of double-strand breaks by NHEJ pathways (Friedland *et al.*
460 2013; Chen *et al.* 2013; Katic and Großhans 2013; Waaijers *et al.* 2013; Dickinson
461 and Goldstein 2016). One, two or more sgRNAs are injected together and phenotypic
462 or PCR screening strategies are used to retrieve deletion mutants by PCR
463 amplification. However, the exact breakpoints of these deletions are not controllable
464 in this scheme and there is always the potential for undesired edits due to off-target
465 effects for each sgRNA.

466 *d10*-entry strains can also serve as a starting point to generate precisely defined
467 gene deletions. As a proof of principle, we targeted the *egl-23* locus. *egl-23* is a large
468 locus comprising 12 exons, and removal of the entire *egl-23a* splice isoform required
469 an 8 kb deletion (Figure 2 Supplement 1). Our goal was to replace the complete *egl-*
470 *23a* locus by a transgene expressing the red fluorescent protein mCherry in the
471 pharynx which could be used as a genetic balancer and knock-out mutant of *egl-23*.
472 We therefore constructed a repair template composed of two homology regions of
473 2 kb, which flanked the transcriptional reporter unit (*Pmyo-2::mCherry::unc-54*
474 *3'UTR*). This construct was then injected into the appropriate *egl-23 d10*-entry strain
475 (JIP1150) along with (i) a Cas9 expression vector (pDD162), (ii) the expression
476 vector for the *d10* sgRNA (pMD8), (iii) the ssON that introduces the *cn64* mutation in
477 *dpy-10* (AF-ZF-827). Out of 40 Dpy-10 progeny, we identified one knock-out line
478 (JIP1253). We validated that the genome edit was accurate by Sanger sequencing.
479 We further verified that the possible off-target site of the *d10* sgRNA was unaffected
480 (Figure 1D). While this particular trial was less efficient than smaller insertions, it
481 confirmed that *d10*-entry strains can – as expected – be used to generate large
482 deletion and gene replacements, in addition to being ideally suited for the insertion of
483 kilobase-sized inserts or epitope tags.

484 Discussion

485 The major conceptual innovation of our strategy is to render genes highly susceptible
486 to CRISPR/Cas9 engineering by transplanting the *d10* sequence. As we have
487 described above, highly effective sgRNAs matching the GGNGG motif are
488 underrepresented in the genome, and are therefore rarely found in close proximity to
489 the region of interest. While editing frequency is highly variable between sgRNAs at
490 different loci or even within the same locus, we found that editing using our *d10*
491 strategy was robust at different loci, with edit frequencies averaging 8 %, i.e. 1 in 12
492 F1 progeny. In addition, editing was also robust at a single locus. This is particularly
493 valuable and time-saving when multiple edits need to be generated in the same
494 locus, as is usually the case when a gene is being characterized in depth. For
495 example, we took advantage of this high editing frequency to rapidly generate
496 multiple chromatic variants in the *twk-18* locus. This allowed us for the first time to
497 precisely compare the resolution and fluorescence intensity of TagBFP, TagRFP-T
498 and the recently published mScarlet. Based on the highly stereotypical distribution
499 pattern of TWK-18 at the muscle surface, we could show that (1) TagBFP fusions
500 provided the best apparent resolution, (2) a codon-optimized wrmScarlet was
501 approximately 8 times brighter than TagRFP-T, (3) the increased signal of
502 wrmScarlet partly compensated for the lesser resolution of red vs. blue fluorescent
503 proteins.

504 One unique feature of our strategy is that edits can be designed so that all original
505 genomic sequences are perfectly preserved. Indeed, by using the transplanted *d10*
506 sgRNA instead of sgRNAs from the targeted locus, no mutations need to be
507 introduced to avoid continued CRISPR/Cas9 activity once the edit is performed. This
508 facilitates and accelerates experimental design, because only one repair template is
509 designed instead of specific repair constructs for each endogenous sgRNA.

510 Another benefit of our strategy is that we could retrieve multiple independent lines
511 from the same injected animal by cloning animals in the F1 generation, which is not
512 possible in strategies that rely on the screening of mixed populations of F2 progeny,
513 e.g. with antibiotic selection strategies. Therefore, since we could focus on relatively
514 few F1 clones, multiple methods could be used to detect the desired genome edit
515 such as direct observation, phenotypic screening or PCR detection. Limiting the
516 number of animals that need to be analyzed, could also mitigate PCR detection
517 issues (see Materials and Methods, PCR screening).

518 From a practical perspective, our strategy provides multiple layers of quality control.
519 Based on the easily detectable *Dpy-10* Co-CRISPR phenotype, we could directly
520 monitor the success of injections and assess the general efficiency of the experiment
521 over time and between experimenters. We could determine if an experiment would
522 likely be successful within three days post-injection, by monitoring the number of
523 marked F1 progeny. Finally, all steps of our protocol are only limited by the
524 generation time of *C. elegans*, making it particularly time-efficient.

525 Obtaining the *d10*-entry strain is the major bottleneck of our strategy. This step, like
526 every CRISPR/Cas9 experiment, relies (1) on the ability to find an endogenous
527 sgRNA that cuts efficiently, and (2) on the rate of homology directed repair at the cut
528 site, which could be influenced by the local genomic context or specific sequence
529 features of the homology arms. Insertion of the *d10* sequence using single-strand
530 oligonucleotides proved highly successful in most cases (Table 1). However, only
531 one of the different sgRNAs we had selected gave us edits, highlighting again the
532 variable efficacy of endogenous sgRNAs. During this study, we were unable to
533 recover *d10* insertions in some of our target loci despite testing multiple sgRNAs. For
534 some genes, we eventually succeeded by using double-stranded DNA repair
535 templates with long homology arms instead of single-strand oligonucleotides.
536 Another avenue we have begun to explore, is to use a CRISPR/Cas9 RNP complex
537 instead of Cas9 expression plasmids. In one experiment, we were able to retrieve
538 two *d10* insertions in this way, while injection of plasmids had been unsuccessful
539 (data not shown).

540 Another practical concern appears when targeting loci that are closely linked to *unc-*
541 *58* (to build *d10* entry strains) or *dpy-10* (to engineer *d10* loci), which are situated at
542 the center of chromosome 2 and X, respectively. Since we select F1 progeny based
543 on mutation of *dpy-10* or *unc-58*, it is likely that genome edits will be linked to these
544 marker mutations. In that case, one should consider the wild-type siblings in the
545 progeny of an injected P0 individual that produced a significant fraction of marked
546 progeny.

547 So far we have tested this strategy only with the *d10* sequence, but in principle, any
548 highly effective sgRNA that targets a gene producing a dominant Co-CRISPR
549 phenotype could be used. Conceptually, our strategy could also be extended to other
550 genetic model organisms. In particular, a co-CRISPR strategy based on the *white*

551 locus has been recently published, and could be a starting point to adapt this strategy
552 to engineer the *Drosophila* genome (Ge *et al.* 2016).

553

554

555 **Acknowledgements**

556 We thank J.-L. Bessereau, I. Katic and members of the Bessereau team for helpful
557 discussion, M. Jospin for comments on the manuscript, and Manuela D'Alessandro
558 for constructing pMD8. pCFJ90 was a gift of Christian Frøkjær-Jensen. We thank
559 Wormbase, which is supported by National Institutes of Health (NIH) grant U41
560 HG002223. This work was supported by a research grant from Fondation Fyssen (T.
561 B.) and an ERC Starting Grant (Project *Kelegans*) (T. B.).

562

563 **Literature Cited**

- 564 Arribere J. A., Bell R. T., Fu B. X. H., Artiles K. L., Hartman P. S., Fire A. Z., 2014
565 Efficient marker-free recovery of custom genetic modifications with CRISPR/Cas9
566 in *Caenorhabditis elegans*. *Genetics* **198**: 837–846.
- 567 Bindels D. S., Haarbosch L., van Weeren L., Postma M., Wiese K. E., Mastop M.,
568 Aumonier S., Gotthard G., Royant A., Hink M. A., Gadella T. W. J., 2017
569 mScarlet: a bright monomeric red fluorescent protein for cellular imaging. *Nat*
570 *Meth* **14**: 53–56.
- 571 Boulin T., Hobert O., 2012 From genes to function: the *C. elegans* genetic toolbox.
572 *WIREs Dev Biol* **1**: 114–137.
- 573 Chai Y., Li W., Feng G., Yang Y., Wang X., Ou G., 2012 Live imaging of cellular
574 dynamics during *Caenorhabditis elegans* postembryonic development. *Nat*
575 *Protoc* **7**: 2090–2102.
- 576 Chen C., Fenk L. A., De Bono M., 2013 Efficient genome editing in *Caenorhabditis*
577 *elegans* by CRISPR-targeted homologous recombination. *Nucleic Acids Res* **41**:
578 e193.
- 579 Cho S. W., Lee J., Carroll D., Kim J.-S., Lee J., 2013 Heritable gene knockout in
580 *Caenorhabditis elegans* by direct injection of Cas9-sgRNA ribonucleoproteins.
581 *Genetics* **195**: 1177–1180.
- 582 Dickinson D. J., Goldstein B., 2016 CRISPR-Based Methods for *Caenorhabditis*
583 *elegans* Genome Engineering. *Genetics* **202**: 885–901.
- 584 Dickinson D. J., Pani A. M., Heppert J. K., Higgins C. D., Goldstein B., 2015
585 Streamlined Genome Engineering with a Self-Excising Drug Selection Cassette.
586 *Genetics* **200**: 1035–1049.
- 587 Dickinson D. J., Ward J. D., Reiner D. J., Goldstein B., 2013 Engineering the
588 *Caenorhabditis elegans* genome using Cas9-triggered homologous
589 recombination. *Nat Meth* **10**: 1028–1034.
- 590 Doench J. G., Fusi N., Sullender M., Hegde M., Vaimberg E. W., Donovan K. F.,
591 Smith I., Tothova Z., Wilen C., Orchard R., Virgin H. W., Listgarten J., Root D. E.,
592 2016 Optimized sgRNA design to maximize activity and minimize off-target
593 effects of CRISPR-Cas9. *Nat Biotechnol* **34**: 184–191.
- 594 Doench J. G., Hartenian E., Graham D. B., Tothova Z., Hegde M., Smith I., Sullender
595 M., Ebert B. L., Xavier R. J., Root D. E., 2014 Rational design of highly active
596 sgRNAs for CRISPR-Cas9-mediated gene inactivation. *Nat Biotechnol* **32**: 1262–
597 1267.
- 598 Doudna J. A., Charpentier E., 2014 Genome editing. The new frontier of genome
599 engineering with CRISPR-Cas9. *Science* **346**: 1258096.
- 600 Farboud B., Meyer B. J., 2015 Dramatic enhancement of genome editing by
601 CRISPR/Cas9 through improved guide RNA design. *Genetics* **199**: 959–971.

El Mouridi *et al.* – *d10*-based genome engineering

- 602 Friedland A. E., Tzur Y. B., Esvelt K. M., Colaiácovo M. P., Church G. M., Calarco J.
603 A., 2013 Heritable genome editing in *C. elegans* via a CRISPR-Cas9 system. *Nat*
604 *Meth* **10**: 741–743.
- 605 Frøkjær-Jensen C., 2013 Exciting prospects for precise engineering of
606 *Caenorhabditis elegans* genomes with CRISPR/Cas9. *Genetics* **195**: 635–642.
- 607 Frøkjær-Jensen C., Davis M. W., Taylor J., Harris T. W., Moerman D. G., Jorgensen
608 E. M., 2010 Targeted gene deletions in *C. elegans* using transposon excision.
609 *Nat Meth*: 1–5.
- 610 Ge D. T., Tipping C., Brodsky M. H., Zamore P. D., 2016 Rapid Screening for
611 CRISPR-Directed Editing of the *Drosophila* Genome Using white Coconversion.
612 *G3 (Bethesda)* **6**: 3197–3206.
- 613 Gendrel M., Rapti G., Richmond J. E., Bessereau J.-L., 2009 A secreted
614 complement-control-related protein ensures acetylcholine receptor clustering.
615 *Nature* **461**: 992–996.
- 616 Gibson D. G., 2011 Enzymatic assembly of overlapping DNA fragments. *Meth*
617 *Enzymol* **498**: 349–361.
- 618 Goedhart J., Stetten von D., Noirclerc-Savoie M., Lelimosin M., Joosen L., Hink M.
619 A., van Weeren L., Gadella T. W. J., Royant A., 2012 Structure-guided evolution
620 of cyan fluorescent proteins towards a quantum yield of 93%. *Nat Commun* **3**:
621 751.
- 622 Heppert J. K., Dickinson D. J., Pani A. M., Higgins C. D., Steward A., Ahringer J.,
623 Kuhn J. R., Goldstein B., 2016 Comparative assessment of fluorescent proteins
624 for in vivo imaging in an animal model system. (S Strome, Ed.). *Mol. Biol. Cell* **27**:
625 3385–3394.
- 626 Hsu P. D., Scott D. A., Weinstein J. A., Ran F. A., Konermann S., Agarwala V., Li Y.,
627 Fine E. J., Wu X., Shalem O., Cradick T. J., Marraffini L. A., Bao G., Zhang F.,
628 2013 DNA targeting specificity of RNA-guided Cas9 nucleases. *Nat Biotechnol*
629 **31**: 827–832.
- 630 Katic I., Großhans H., 2013 Targeted heritable mutation and gene conversion by
631 Cas9-CRISPR in *Caenorhabditis elegans*. *Genetics* **195**: 1173–1176.
- 632 Katic I., Xu L., Ciosk R., 2015 CRISPR/Cas9 Genome Editing in *Caenorhabditis*
633 *elegans*: Evaluation of Templates for Homology-Mediated Repair and Knock-Ins
634 by Homology-Independent DNA Repair. *G3 (Bethesda)* **5**: 1649–1656.
- 635 Kelly W. G., Fire A., 1998 Chromatin silencing and the maintenance of a functional
636 germline in *Caenorhabditis elegans*. *Development* **125**: 2451–2456.
- 637 Kim H., Ishidate T., Ghanta K. S., Seth M., Conte D., Shirayama M., Mello C. C.,
638 2014 A co-CRISPR strategy for efficient genome editing in *Caenorhabditis*
639 *elegans*. *Genetics* **197**: 1069–1080.
- 640 Kunkel M. T., Johnstone D. B., Thomas J. H., Salkoff L., 2000 Mutants of a

- 641 temperature-sensitive two-P domain potassium channel. *J. Neurosci.* **20**: 7517–
642 7524.
- 643 Levy A. D., Yang J., Kramer J. M., 1993 Molecular and genetic analyses of the
644 *Caenorhabditis elegans* *dpy-2* and *dpy-10* collagen genes: a variety of molecular
645 alterations affect organismal morphology. *Mol. Biol. Cell* **4**: 803–817.
- 646 Norris A. D., Kim H.-M., Colaiácovo M. P., Calarco J. A., 2015 Efficient Genome
647 Editing in *Caenorhabditis elegans* with a Toolkit of Dual-Marker Selection
648 Cassettes. *Genetics* **201**: 449–458.
- 649 Paix A., Folkmann A., Rasoloson D., Seydoux G., 2015 High Efficiency, Homology-
650 Directed Genome Editing in *Caenorhabditis elegans* Using CRISPR-Cas9
651 Ribonucleoprotein Complexes. *Genetics* **201**: 47–54.
- 652 Paix A., Wang Y., Smith H. E., Lee C.-Y. S., Calidas D., Lu T., Smith J., Schmidt H.,
653 Krause M. W., Seydoux G., 2014 Scalable and versatile genome editing using
654 linear DNAs with microhomology to Cas9 Sites in *Caenorhabditis elegans*.
655 *Genetics* **198**: 1347–1356.
- 656 Redemann S., Schloissnig S., Ernst S., Pozniakowsky A., Ayloo S., Hyman A. A.,
657 Bringmann H., 2011 Codon adaptation-based control of protein expression in *C.*
658 *elegans*. *Nat Meth* **8**: 250–252.
- 659 Robert V., Bessereau J.-L., 2007 Targeted engineering of the *Caenorhabditis*
660 *elegans* genome following *Mos1*-triggered chromosomal breaks. *EMBO J* **26**:
661 170–183.
- 662 Schwartz M. L., Jorgensen E. M., 2016 SapTrap, a Toolkit for High-Throughput
663 CRISPR/Cas9 Gene Modification in *Caenorhabditis elegans*. *Genetics* **202**:
664 1277–1288.
- 665 Shaner N. C., Lambert G. G., Chammas A., Ni Y., Cranfill P. J., Baird M. A., Sell B.
666 R., Allen J. R., Day R. N., Israelsson M., Davidson M. W., Wang J., 2013 A bright
667 monomeric green fluorescent protein derived from *Branchiostoma lanceolatum*.
668 *Nat Meth* **10**: 407–409.
- 669 Shaner N. C., Lin M. Z., McKeown M. R., Steinbach P. A., Hazelwood K. L.,
670 Davidson M. W., Tsien R. Y., 2008 Improving the photostability of bright
671 monomeric orange and red fluorescent proteins. *Nat Meth* **5**: 545–551.
- 672 Waaijers S., Portegijs V., Kerver J., Lemmens B. B. L. G., Tijsterman M., van den
673 Heuvel S., Boxem M., 2013 CRISPR/Cas9-targeted mutagenesis in
674 *Caenorhabditis elegans*. *Genetics* **195**: 1187–1191.
- 675 Ward J. D., 2015 Rapid and precise engineering of the *Caenorhabditis elegans*
676 genome with lethal mutation co-conversion and inactivation of NHEJ repair.
677 *Genetics* **199**: 363–377.
- 678 Zetsche B., Gootenberg J. S., Abudayyeh O. O., Slaymaker I. M., Makarova K. S.,
679 Essletzbichler P., Volz S. E., Joung J., van der Oost J., Regev A., Koonin E. V.,
680 Zhang F., 2015 Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-

El Mouridi *et al.* – *d10*-based genome engineering

681 Cas system. *Cell* **163**: 759–771.

682 Zhao P., Zhang Z., Ke H., Yue Y., Xue D., 2014 Oligonucleotide-based targeted gene
683 editing in *C. elegans* via the CRISPR/Cas9 system. *Nature Publishing Group* **24**:
684 247–250.

685

686 **Tables**

687

688 **Table 1:** Insertion of *d10* protospacer at four genomic loci.

Gene (WormBase ID)	Proportion of Unc-58-marked progeny with <i>d10</i> site	Proportion of wild-type siblings with <i>d10</i> site
<i>sup-9 II</i> (WBGene00006318)	14/39 (35%)	3/14 (21%)
<i>egl-23b IV</i> (WBGene00001190)	9/13 (69%)	6/108 (6%)
<i>egl-23 IV</i> (WBGene00001190)	8/8 (100%)	
<i>twk-18 X</i> (WBGene00006672)	0/1	7/93 (7%)

689

690

691 **Table 2:** High CRISPR/Cas9 activity at transplanted *d10* site.


Gene (WormBase ID)	Number of marked F1 progeny	Number of clones lacking B _{an} I site	Number of clones lacking B _{sr} BI [+B _{ss} SI] site	Combined number of clones lacking restriction sites
<i>tag-68 I</i> (WBGene00006445)	45	11 (24%)	10 (22 %)	21 (47%)
<i>egl-23 IV</i> (WBGene00001190)	43	7 (16%)		
<i>twk-18 X</i> (WBGene00006672)	36	5 (14%)	4 [+3] (19%)	12 (33%)
<i>unc-58 X</i> (WBGene00006792)	42	11 (26%)	11 (26%)	22 (52%)

692

693

694 **Table 3:** Summary of genome editing experiments.

Gene (WormBase ID)	Inserted sequence	Proportion of P0 with Dpy-10 progeny	Proportion of Dpy-10-marked F1 progeny with edits	Percentage edits per Dpy-10-marked F1 progeny
<i>sup-9 II</i> (WBGene00006318)	TagRFP-T	11/42	4/142	3%
<i>twk-40 III</i> (WBGene00006691)	TagRFP-T::ZF1	16/35	3/45	7%
<i>egl-23 IV</i> (WBGene00001190)	TagRFP-T	12/60	5/79	6%
	SL2::TagRFP-T	9/63	3/37	8%
	TagBFP	10/24	5/27	19%
	TagBFP2	10/33	7/68	10%
	wrmScarlet	19/35	14/190	7%
	Myc-Myc	8/30	9/67	14%
<i>twk-18 X</i> (WBGene00006672)	TagRFP-T	5/27	5/77	6%
	TagBFP	4/20	6/98	6%
	wrmScarlet	11/29	6/123	5%







Figure 2 Supplement 1





Figure 3



695 **Figure Legends**

696

697 **Figure 1 Generation of *d10*-entry strains**

698 **A** Insertion of the *d10* sequence into **(Aa)** *egl-23b*, **(Ab)** *egl-23 C-term*, **(Ac)** *sup-9*,
699 and **(Ad)** *twk-18* using a single-strand oligonucleotide repair template compatible with
700 multiple sgRNAs. Genes and their intron/exon structure are displayed in the 5' to 3'
701 orientation. The ssON repair templates are represented by black arrows (containing
702 the *d10* sequence in green) above the coding strand and translation of the target
703 gene. Correspondence of homology regions between the ssON repair template and
704 genomic locus is indicated in gray. sgRNA binding sites are indicated by blue open
705 arrows.

706 **B** *unc-58* co-conversion is used to detect the insertion of *d10* sequences into a gene
707 of interest. *unc-58(e665)* mutants are easily identified in the F1 progeny of injected
708 P0 animals based on their straight body posture, lack of mobility and characteristic
709 rotation around the antero-posterior body axis. RT, repair template.

710 **C** *Ban*I, *Bss*SI, and *Bsr*BI restriction sites are present in the *d10* protospacer
711 sequence and are used for RFLP analysis. The Cas9 double-strand break site is
712 indicated by an arrowhead.

713 **D** *R12E2.15* contains the only predicted off-target site of the *d10* sgRNA. Four base
714 changes (in pink) distinguish both sites. A *Bsr*BI site follows the Cas9 double-strand
715 break site (indicated by an arrowhead), between the -3 and -4 bases relative to the
716 protospacer adjacent motif (PAM).

717

718 **Figure 2 Generation of multiple knock-in lines using a single *d10*-entry strain**

719 **A** A single *d10*-entry strain is used to engineer N-terminal TagBFP, TagRFP-T, and
720 *wrmScarlet* fusions in the *twk-18* locus. Correspondence of homology regions
721 between the plasmid repair template and *twk-18* genomic locus is indicated in gray.
722 RT, repair template.

723 **B** Two to three days following injection of a *d10*-entry strain with a CRISPR/Cas9
724 mix, F1 progeny with Dpy-10 phenotypes (Rol or Dpy) can be easily recovered, and
725 further screened in the F2 generation to identify the desired genome edits by PCR or
726 phenotype.

727

728 **Figure 2 Supplement 1**

729 **A** Insertion of a 2xMyc tag into the *egl-23* locus using a single-strand DNA template.
730 Correspondence of homology regions between the ssON repair template and
731 genomic locus is indicated in gray. The sequence of the resulting fusion protein is
732 indicated below the DNA sequence with single-letter amino acid code. Black bars
733 labeled “Myc” indicate the position of the *myc* tag sequences.

734 **B** Deletion and replacement of the *egl-23a* locus by a *Pmyo-2::mCherry* reporter
735 transgene. Correspondence of homology regions between the plasmid repair
736 template (pCL7) and genomic locus is indicated in gray. The *Pmyo-2::mCherry::unc-*
737 *54 3'UTR* transgene is inserted in the reverse orientation relative to the *egl-23* gene.

738

739 **Figure 3 Comparison of TagBFP, TagRFP-T and wrmScarlet using reliable**
740 **editing of the *twk-18* locus**

741 **A** wrmScarlet::TWK-18 is visibly brighter than TagRFP-T::TWK-18. Side-by-side
742 comparison of two young adult hermaphrodites. wrmScarlet-associated fluorescence
743 is visible by eye in freely moving worms on NGM plates, while TagRFP-T is not
744 detectable by eye in this context.

745 **B** The two-pore domain potassium channel TWK-18 decorates the plasma
746 membrane of body wall muscle cells. Representative images of head muscle cells
747 labeled with N-terminal fusions of TWK-18 to TagBFP, TagRFP-T, and wrmScarlet.
748 Head is left. Scale bars, 10 μ m.

749 **C** Quantification of fluorescence intensity shows an 8-fold increase in fluorescence
750 between TagRFP-T and wrmScarlet. Mean \pm standard deviation. Student's *t*-test,
751 * < 0.0001.

752

753

754 **Figure 3 Supplement 1**

755 **A** Codon-optimized wrmScarlet vs mScarlet sequence alignment.

756 **B** Schematic representation of the pSEM87 *wrmScarlet::twk-18 repair template*. LHR
757 and RHR indicate left and right homology regions, respectively. The five first exons of
758 *twk-18* present in the RHR are indicated in yellow. Scale bar in base pairs.

759 **C** 5' junction of wrmScarlet to *twk-18*. The sequence of the resulting fusion protein is
760 indicated below the DNA sequence with single-letter amino acid code and
761 corresponding amino acid positions.

El Mouridi *et al.* – *d10*-based genome engineering

762 **D** 3' junction of *wrmScarlet* to *twk-18*. The sequence of the resulting fusion protein is
763 indicated below the DNA sequence with single-letter amino acid code and
764 corresponding amino acid positions.
765

766 **Supplementary Tables**

767

768 **Supplementary Table 1: Prevalence of GNNG and GGNGG protospacers in and**
 769 **close to exons of two-pore domain potassium channel genes.**

770

Gene	NGG	GNNG	GGNGG	GNNG/NGG	GGNGG/NGG
<i>egl-23</i>	226	59	23	0.26	0.10
<i>sup-9</i>	115	27	10	0.23	0.09
<i>unc-58</i>	181	33	9	0.18	0.05
<i>twk-3</i>	85	8	2	0.09	0.02
<i>twk-6</i>	70	10	2	0.14	0.03
<i>twk-8</i>	70	10	2	0.14	0.03
<i>twk-12</i>	134	26	6	0.19	0.04
<i>twk-13</i>	190	49	19	0.26	0.10
<i>twk-14</i>	122	23	8	0.19	0.07
<i>twk-16</i>	146	34	10	0.23	0.07
<i>twk-17</i>	185	40	13	0.22	0.07
<i>twk-18</i>	121	18	6	0.15	0.05
<i>twk-20</i>	108	17	5	0.16	0.05
<i>twk-23</i>	118	29	7	0.25	0.06
<i>twk-24</i>	102	25	5	0.25	0.05
<i>twk-25</i>	166	25	6	0.15	0.04
<i>twk-28</i>	132	22	5	0.17	0.04
<i>twk-30</i>	139	25	7	0.18	0.05
<i>twk-32</i>	148	33	8	0.22	0.05
<i>twk-40</i>	148	33	8	0.22	0.05
<i>twk-44</i>	195	43	6	0.22	0.03
<i>twk-46</i>	132	31	5	0.23	0.04
Average ratios				0.20	0.05

771

772 **Supplementary Table 2: Strain list**
773

Strain	Genotype	Description
JIP1141-2	<i>tag-68(bln209) I</i> <i>tag-68(bln212) I</i>	Insertion of <i>d10</i> site in 5' of <i>tag-68</i>
JIP1155-7	<i>sup-9(bln224) II</i> <i>sup-9(bln225) II</i> <i>sup-9(bln226) II</i>	Insertion of <i>d10</i> site in 5' of <i>sup-9</i>
JIP1127, JIP1129	<i>egl-23(bln172) IV</i> <i>egl-23(bln179) IV</i>	Insertion of <i>d10</i> site in 5' of <i>egl-23b</i>
JIP1149-50	<i>egl-23(bln219) IV</i> <i>egl-23(bln220) IV</i>	Insertion of <i>d10</i> site in 3' of <i>egl-23</i>
JIP1143	<i>twk-18(bln213) X</i>	Insertion of <i>d10</i> site in 5' of <i>twk-18</i>
JIP1152	<i>tag-68(bln222) I</i>	Insertion of TagRFP-T in <i>tag-68</i> at 5'
JIP1224-6	<i>sup-9(bln236) II</i> <i>sup-9(bln237) II</i> <i>sup-9(bln238) II</i>	Insertion of TagRFP-T in <i>sup-9</i> at 5'
JIP1368-70	<i>twk-40(bln282) III</i> <i>twk-40(bln283) III</i> <i>twk-40(bln284) III</i>	Insertion of TagRFP-T::ZF1 in <i>twk-40</i> at 3'
JIP1171-5	<i>egl-23(bln227) IV</i> <i>egl-23(bln228) IV</i> <i>egl-23(bln229) IV</i> <i>egl-23(bln230) IV</i> <i>egl-23(bln231) IV</i>	Insertion of TagRFP-T in <i>egl-23</i> at 3'
JIP1221-3	<i>egl-23(bln233) IV</i> <i>egl-23(bln234) IV</i> <i>egl-23(bln235) IV</i>	Insertion of SL2::TagRFP-T in <i>egl-23</i> at 3'
JIP1336	<i>egl-23(bln277) IV</i>	Insertion of TagBFP in <i>egl-23</i> at 3'
JIP1448-50	<i>egl-23(bln309) IV</i> <i>egl-23(bln310) IV</i> <i>egl-23(bln311) IV</i>	Insertion of wrmScarlet in <i>egl-23</i> at 3'
JIP1233-5	<i>twk-18(bln246) X</i> <i>twk-18(bln247) X</i> <i>twk-18(bln248) X</i>	Insertion of TagRFP-T in <i>twk-18</i> at 5'
JIP1236, JIP1251-2	<i>twk-18(bln249) X</i> <i>twk-18(bln250) X</i> <i>twk-18(bln251) X</i>	Insertion of TagBFP in <i>twk-18</i> at 5'
JIP1440-42	<i>twk-18(bln304) X</i> <i>twk-18(bln305) X</i> <i>twk-18(bln306) X</i>	Insertion of wrmScarlet in <i>twk-18</i> at 5'
JIP1328-9, JIP1331	<i>egl-23(bln269) IV</i> <i>egl-23(bln270) IV</i> <i>egl-23(bln272) IV</i>	Insertion of 2xMyc sequence in <i>egl-23</i> at 3'
JIP1253	<i>egl-23(bln252[Pmyo-2::mCherry::3'UTR unc-54])IV</i>	Deletion and replacement of <i>egl-23a</i> by <i>Pmyo-2::mCherry::3' UTR unc-54</i>

774
775

776 **Supplementary Table 3: List of single strand oligonucleotides**
777

Primer	Sequence (5' to 3')	Description
AF-ZF-827	CACTTGAACCTCAATACGGCAAGATGAGAATGA CTGGAACCGTACCGCATGCGGTGCCTATGGTAG CGGAGCTTCACATGGCTTCAGACCAACAGCCTAT	ssDNA repair template; <i>dpy-10(cn64)</i>
AF-JA-76	ATTTTGTGGTATAAAATAGCCGAGTTAGGAAAC AAATTTTCTTTTCAGTTTTCTCAGTAGTGACCA TGTGCGTGGATCTTGCCTCCACACATCTCAAGG CGTACTT	ssDNA repair template; <i>unc-58(e665)</i>
oSEM158	Gaaagcaagaaatcatcacatttgagtggctcat cgagaagagaaagcgggtggaagGAGGAGAACA AAAGTTGATTTCTGAAGAAGATTTGAACGGTGAA CAAAAGCTAATCTCCGAGGAAGACTTGtaattaa Aacttgtaatttttaatagaaataaagttttg tgctacgaattt	ssDNA repair template; insertion of 2xMyc sequence in <i>egl-23</i> at 3' <i>d10</i> site
oPT85	AACTACAGTATCCCAACTGATTGTGGTAACACATC ACGGCATGCACCACGGCTACCATAGGCACCACGAG CGGGATTGTGGCATGTGGTGTGTTCAGCGAGAG GCGGCGACACGTCGAGAG	ssDNA repair template; insertion of <i>d10</i> sequence in <i>tag-68</i>
oSEM40	TGTGAGCTCAGCAGCTTCTCGTCGTTTCTTTTTT GTATAAATTTGAAGAGCTACCATAGGCACCACGAG CGGACACTTATCGTCTGCACACTGACCTACCTTT AGTTGGAGCAGCCGTATTT	ssDNA repair template; insertion of <i>d10</i> sequence in <i>sup-9</i>
oCL60	CCGGAAAGCAAGAAATCATCATTGAGTGGCTC ATCGAGAAGAGAAAGCGGGCTACCATAGGCACCAC GAGCGGTTAAAACCTGTGTAATTTTAAATGAAAAT AAAGTTTTGTGCTACGAATTT	ssDNA repair template; insertion of <i>d10</i> sequence in <i>egl-23</i> at 3' <i>d10</i> site
oCL58	TCTAAACATTTTCATTCTTCTCATTCCGTCACCCC ATTCTGTTCCCGAATCGCTACCATAGGCACCACG AGCGGGAATCAAAAACCTGCAATTTTCGAAAAGTAA GTTGGCCTTTTTGTGGGAAA	ssDNA repair template; insertion of <i>d10</i> sequence in <i>egl-23b</i>
oCL75	AGGTAGTACACGAAAGGTAGGAGGCAAGCGGGTGA CAAAAACAACCGAAGCTACCATAGGCACCACGAG CGGGCGATTGTTGCGCAAGGAGTTTCTACGATTTT GACGACGTTTCAGAAAAC	ssDNA repair template; insertion of <i>d10</i> sequence in <i>twk-18</i>
oSEM171	gtgaatgatcacgcacgata	Primer pair for amplification of <i>d10</i> off-target site in <i>R12E2.15</i>
oSEM172	gtactgtggtggtggtggtg	
oCL77	CCAACCCCTCTCATCCTTTT	Primer pair for amplification of <i>d10</i> site in <i>twk-18(bln213)</i>
oCL78	TTTCATAGTCGATTTTCATTGAGA	
oPT95	GAAAATTTGGAACCGGGCTA	Primer pair for amplification of <i>d10</i> site in <i>tag-68(bln212)</i>
oTB586	CAACGTCTTCTGCATCGAAA	
oSEM31	ATGAACCTCCTAGTGCTCCG	Primer pair for amplification of <i>d10</i> site in <i>sup-9(bln226)</i>
oSEM32	GGAAATGGGCTCTCGTTGTG	
oCL44	AAAGCGTACAGCGAAGAAGC	Primer pair for amplification of <i>d10</i> site in <i>egl-23(bln220)</i>
oCL34	TTCCAAGCATATTTGTGATCG	
oCL45	CGATTGTGAGCCAATGAGAA	Primer pair for amplification of <i>d10</i> site in <i>egl-23b(bln172)</i>
oCL46	CGTTTTCAATTTTCCATGC	
oSEM140	GCCAAAAGAAGACCCATGAC	Primer pair for amplification of <i>d10</i> site in <i>twk-40(bln271)</i>
oSEM141	AAAAATCGCTCTAAATTTCCAGTT	

778 **Supplementary Table 4: List of plasmids**
779

Plasmid/ locus	Primer	Sequence (5' to 3')	Description
pSEM91/ <i>egl-23</i>	oCL101	ActcactatagggggcgcgCctcgacctgcaggtcgagctGGCTA TATGGTTTGGAGGAA	LHR amplification
	oSEM275	TTTTCCACCGCTTTCTCTTC	
	oSEM276	AcatttgagtggtcctcatcgaGaaagagaaagcggtggaaaaATGGT CAGCAAGGGAGAGGC	wrmScarlet amplification
	oSEM277	AaaactttattttcattaaaAattacacaagttttaattaCTTGT AGAGCTCGTCCATTC	
	oSEM278	TTAAAACCTTGTAATTTTT	RHR amplification
	oCL106	TtctggccttttgctggccttttgctcacatggcagCATGCAGT CGAGACATTTACATC	
pCL16/ <i>egl-23</i>	oCL101	ActcactatagggggcgcgCctcgacctgcaggtcgagctGGCTA TATGGTTTGGAGGAA	LHR amplification
	oCL102	GcatgttctccttaatacagctcttcgccttagacacccatTTTTC CACCGCTTTCTCTTC	
	oCL103	AcatttgagtggtcctcatcgaGaaagagaaagcggtggaaaaATGGT GTCTAAGGCCGAAGA	TagRFP-T amplification
	oCL104	CacaaaactttattttcattaaaattacacaagttttaTTAAT TAAGTTTGTGCCCA	
	oCL105	CtgcgacctccctagcaaaactggggcacaaacttaattaaTTAAA ACTTGTGTAATTTTTAATGAAAATAAAGTTTTGTGCTACGA	RHR amplification
	oCL106	ttctggccttttgctggccttttgctcacatggcagCATGCAGT CGAGACATTTACATC	
pCL22/ <i>egl-23</i>	oCL101	ActcactatagggggcgcgCctcgacctgcaggtcgagctGGCTA TATGGTTTGGAGGAA	LHR amplification
	oCL127	acaagcagttactaggtgaaagtaggatgagacagcTTATTTTC CACCGCTTTCTCTTC	
	oCL128	tgagtggtcctcatcgaGaaagagaaagcggtggaaaaataaGCTGTCT CATCCTACTTTCACC	SL2::TagRFP-T amplification
	oCL104	CacaaaactttattttcattaaaattacacaagttttaTTAAT TAAGTTTGTGCCCA	
	oCL105	CtgcgacctccctagcaaaactggggcacaaacttaattaaTTAAA ACTTGTGTAATTTTTAATGAAAATAAAGTTTTGTGCTACGA	RHR amplification
	oCL106	ttctggccttttgctggccttttgctcacatggcagCATGCAGT CGAGACATTTACATC	
pSEM67/ <i>egl-23</i>	oCL101	actcactatagggggcgcgCctcgacctgcaggtcgagctGGCTA TATGGTTTGGAGGAA	LHR amplification
	oSEM142	tgtacagtttcatatgcatattctccttaataagctctgatTTTC CACCGCTTTCTCTTC	
	oSEM143	TCAGAGCTTATTAAGGAGAA	TagBFP amplification
	oSEM146	aaaactttattttcattaaaattacacaagttttaattaATTAA GCTTGTGACCCAGTT	
	oSEM145	CGCAAACGCCAAGACCACATATAGATCCAAGAAACCG	TagBFP2 point mutation
	oSEM144	TTTCTTGATCTATATGTGGTCTTGGCGTTTGGATGAGATGGCT ACCGC	
	oSEM147	CtgcgacctcccagcaaaactgggtcacaagcttaattaTAAA ACTTGTGTAATTTTT	RHR amplification
	oCL106	TtctggccttttgctggccttttgctcacatggcagCATGCAGT CGAGACATTTACATC	
pSEM69/ <i>egl-23</i>	oCL101	actcactatagggggcgcgCctcgacctgcaggtcgagctGGCTA TATGGTTTGGAGGAA	LHR amplification
	oSEM142	tgtacagtttcatatgcatattctccttaataagctctgaTTTTC	

El Mouridi *et al.* – *d10*-based genome engineering

		CACCGCTTCTCTTC	
	oSEM143	TCAGAGCTTATTAAGGAGAA	TagBFP amplification
	oSEM146	aaaactttattttcattaaaaattacacaagttttaattaATTAA GCTTGTGACCCAGTT	
	oSEM147	ctgcgacctcccagcaaaactgggtcacaagcttaattaatTAAA ACTTGTGTAATTTTT	RHR amplification
	oCL106	ttcctggccttttgctggccttttgctcacatggcagCATGCAGT CGAGACATTTACATC	
pSEM55/ <i>sup-9</i>	oSEM75	gactcactatagggggcgcgctcgacctgcaggtcgagcGTGCA GCAGGAAGTGATGGA	LHR amplification
	oSEM74	TCTTCAAATTTATACAAAAAAGAAACGACGAGAAGCTGCTGA	
	oSEM63	gcagcttctcgtcgtttctttttgtataaattgaagaATGGT GTCTAAGGGCAAGA	TagRFP-T amplification
	oSEM72	tgcagacgataagtgcaggggttctgatattttggcgcttATTAA GTTTGTGCCCCAGTT	
	oSEM77	AAGCGCCAAAATATCAGAACCC	RHR amplification
	oSEM76	cggttcttggccttttgctggccttttgctcacatggcagTAGTC ATCCCGAAAACGTC	
pSEM61/ <i>twk-18</i>	oCL117	gactcactatagggggcgcgctcgacctgcaggtcgagcATGGG AATTGGTGCATTTTC	LHR amplification
	oSEM123	TTCCGGTTGTTTTTGTCACC	
	oSEM125	aaggttaggaggaagcgggtgacaaaaacaaccggaatgTCAGA GCTTATTAAGGAGAA	TagBFP amplification
	oSEM128	acgtcgtcaaaatcgtagaaactccttgcgcaacaatcgcATTAA GCTTGTGACCCAGTT	
	oSEM127	GCGATTGTTGCGCAAGGAGT	RHR amplification
	oCL120	cggttcttggccttttgctggccttttgctcacatggcagGTGAA CAAGACCGCACAGAA	
pCL17/ <i>twk-18</i>	oCL117	gactcactatagggggcgcgctcgacctgcaggtcgagcATGGG AATTGGTGCATTTTC	LHR amplification
	oCL118	gcatgttctccttaatcagctcttgccttagacacatTTCCG GTTGTTTTTGTCACC	
	oCL91	cgaaggtaggaggcaagcgggtgacaaaaacaaccggaatgTCAGA GTCTAAGGGCAAGA	TagRFP-T amplification
	oCL92	acgtcgtcaaaatcgtagaaactccttgcgcaacaatcgcATTAA GTTTGTGCCCCAGTT	
	oCL119	actgcgacctccctagcaaaactggggcacaaacttaatgcGATTG TTGCGCAAGGAGTTT	RHR amplification
	oCL120	cggttcttggccttttgctggccttttgctcacatggcagGTGAA CAAGACCGCACAGAA	
pSEM87/ <i>twk-18</i>	oCL117	gactcactatagggggcgcgctcgacctgcaggtcgagcATGGG AATTGGTGCATTTTC	LHR amplification
	oSEM123	TTCCGGTTGTTTTTGTCACC	
	oSEM127	GCGATTGTTGCGCAAGGAGT	RHR amplification
	oCL120	cggttcttggccttttgctggccttttgctcacatggcagGTGAA CAAGACCGCACAGAA	
pSEM80/ <i>twk-40</i>	oSEM135	ccgccagatcttccgatggctcgagtttttcagcaagaTAAGGA CGTTGCAATTAATC	LHR amplification
	oSEM136	aataagctagaccgctcgtggtgcctatggttagcaccgTTCAA TTGAGGCAATGCTC	
	oSEM137	attgaaccggtgctaccataggcaccacgagcggtgcttagCTTAT TTTTAGATTAATTGT	RHR amplification
	oSEM138	atggcagctgagaatattgtaggagatcttctagaaagaTTTTTG GCGAAAATTCAGGT	

El Mouridi *et al.* – *d10*-based genome engineering

	oMM7	gatttatcgattttggagcattggcctcaattgaaagttggcaat cgctatggtcaattctcactggaagaactcaagaagttcatgtta tggtgtctaagggcgaagagctgattaagg	TagRFP-T amplification
	oTB600	acaccgtaaaacaaaaaaaaacacacaattaatctaaaaa taaggatccgccactacctccagagccaccATTAAGTTTGTGCC CAGTTTGC	
	oTB601	cacaaacttaatggtggctctggaggtagtggcgGAACAGAATAC AAAACGCGACTTTGTGATGCGTTCCGCCGTGAAGGATACTGCCC TACAACGACAATTGCACATATGCTCACGGACAAGATGAGCTGAGA GTTCCGTAActatTTTTtagattaattgtgtttgtTTTTTTTTTg TTTTaacgggtg	Integration of ZF1 sequence
pPT46/ <i>tag-68</i>	oPT86	aattgcaaatctaaatgtttCCACATGCCACAATCCATCGgtttt agagctagaaatagc	Forward primer
	oPT87	gctatcttagctctaaaacCGATGGATTGTGGCATGTGGaaaca tttagatttgcaatt	Reverse primer
pPT47/ <i>tag-68</i>	oPT88	gctatcttagctctaaaacCAATCCATCGTGGTGCATGCaaaca tttagatttgcaatt	Forward primer
	oPT89	gctatcttagctctaaaacCAATCCATCGTGGTGCATGCaaaca tttagatttgcaatt	Reverse primer
pSEM46/ <i>sup-9</i>	oSEM27	aatgcaaatctaaatgtttCCACATGCCACAATCCATCGgtttta gagctagaaatagc	Forward primer
	oSEM28	gctatcttagctctaaaacAAATATTAAGAAGAAGCTGCaaaca tttagatttgcaatt	Reverse primer
pSEM48/ <i>sup-9</i>	oSEM43	aattgcaaatctaaatgtttGTGTGCAGACGATAAGTGACgtttt agagctagaaatagc	Forward primer
	oSEM44	gctatcttagctctaaaacGCACTTATCGTCTGCACACaaaca tttagatttgcaatt	Reverse primer
pSEM50/ <i>sup-9</i>	oSEM47	aattgcaaatctaaatgtttGTGTGCAGACGATAAGTGACgttt tagagctagaaatagc	Forward primer
	oSEM48	ctatcttagctctaaaacTGCACTTATCGTCTGCACACaaaca tttagatttgcaatt	Reverse primer
pCL11/ <i>egl-23</i>	oCL67	attgcaaatctaaatgtttGTATCGAGAAGAGAAAGCGGgtttt agagctagaaatagc	Forward primer
	oCL68	gctatcttagctctaaaacCCGCTTTCTCTTCTCGATGACaaac atntagatttgcaatt	Reverse primer
pCL8/ <i>egl-23b</i>	oCL61	attgcaaatctaaatgtttGCCATTCTGTTCCCGAATCagtttt agagctagaaatagc	Forward primer
	oCL62	gctatcttagctctaaaactGATTCCGGGAACAGAATGGcaaac atntagatttgcaatt	Reverse primer
pCL9/ <i>egl-23b</i>	oCL63	attgcaaatctaaatgtttGAGTTTTTATTCCATGATTCgtttt agagctagaaatagc	Forward primer
	oCL64	gctatcttagctctaaaacGAATCATGGAATCAAAAACCTCaaac atntagatttgcaatt	Reverse primer
pCL12/ <i>twk-18</i>	oCL69	aattgcaaatctaaatgtttGTGACAAAACAACCGGAAAggtttt agagctagaaatagc	Forward primer
	oCL70	gctatcttagctctaaaacTTCCGGTTGTTTTGTGACaaaca tttagatttgcaatt	Reverse primer
pCL13/ <i>twk-18</i>	oCL71	attgcaaatctaaatgtttTGCGCAACAATCGCCATTTGgtttt agagctagaaatagc	Forward primer
	oCL72	gctatcttagctctaaaacGAAATGGCGATTGTTGCGCaaaac atntagatttgcaatt	Reverse primer
pMM1/ <i>twk-40</i>	oMM1	AATTGCAATCTAAATGTTTgattggcctcaattgaaagtGTTT TAGAGCTAGAAATAGC	Forward primer
	oMM2	GCTATTTCTAGCTCTAAAACACTTTCAATTGAGGCAATGCAAAC ATTTAGATTGCAATT	Reverse primer

781 **Supplementary Methods**

782

783 **Building sgRNA expression vectors using pPT2**

784

785 This protocol describes the steps and tools used to generate sgRNA expression vectors
786 using the pPT2 vector backbone. See the materials and methods section for the
787 required reagents (e.g. Gibson assembly reagents, sequencing primers).

788 We use the excellent online service www.benchling.com for sgRNA, oligo and vector
789 design.

790

791 **I) Identifying a suitable protospacer motif**

792 • A protospacer is a 19-20 bp sequence flanked at its 3' end by an NGG PAM
793 (protospacer adjacent motif). Different online tools are available to identify possible
794 protospacers in a region of interest (crispr.mit.edu ; tefor.net/crispor/crispor.cgi ;
795 benchling.com).

796 • When multiple protospacer sequences are possible, select the closest (to the site to
797 engineer) and/or the most specific sequence (use the off-target prediction tool
798 provided by [benchling](http://benchling.com) for example). In general, four non-matching bases should be
799 enough to significantly reduce off-target cutting, especially if the mismatches are
800 located in the 3' region of the protospacer (Hsu *et al.* 2013).

801

802 **II) Building the sgRNA vector sequence *in silico***

803 • The pPT2 vector contains the U6 promoter and 3' UTR of *KO9B11.12* (Friedland *et al.*
804 2013) and two restriction sites (PmeI and SexAI) to linearize the vector, followed by the
805 invariant sgRNA scaffold sequence (see Figure 1A).

806 • To generate the sgRNA expression vector sequence, insert the protospacer sequence
807 (**without** the PAM, i.e. NGG) between the U6 promoter and the sgRNA scaffold as
808 shown in figure 1B.


809 • If the selected protospacer sequence does not begin with a guanine residue, add this
810 nucleotide manually to the 5' of the protospacer (i.e. resulting in a "19+1" bp insertion in
811 pPT2 since this protospacer is only 19 bp, see figure 1B).

812 • Name this vector pXYn where XY are the initials of the person building the vector and
813 n the number of the vector. Accordingly, the protospacer sequence is then labeled
814 CRpXYn (generate a "feature" with the sequence to identify it easily in the genomic
815 sequence).

816 • Generate one 60 bp oligonucleotide centered on the protospacer sequence as shown
817 in figure 1C (forward or reverse). **Gibson assembly can be performed with a single
818 primer.** Alternatively, generate two complementary 60 bp oligonucleotides centered on
819 the protospacer sequence as shown in figure 1C.

820

El Mouridi *et al.* – *d10*-based genome engineering



821
822 **Figure 1 - Insertion of a protospacer sequence into the pPT2 sgRNA expression vector.**
823 Note that a single primer (forward or reverse) is sufficient to complete the Gibson
824 assembly reaction.

825 **III) Building the sgRNA vector**

826 The protospacer sequence is incorporated into the pPT2 vector as follows:

827
828 **1 | Gibson assembly**

- 829 • Thaw an aliquot of Gibson Master Mix and keep on ice.
830 • Mix 100 ng of linearized pPT2 vector with 1 μ L of 100 μ M (or 0.1 nmole) of single
831 strand oligonucleotide and add water up to 5 μ L if necessary.
832 • Add 15 μ L of Gibson Master Mix to the DNA mix.
833 • Incubate at 50°C for 15 to 60 minutes (60 minutes is optimum).
834 • Transform 5 μ L of this reaction, and grow on LB+Ampicilin plates.
835 • Perform a control experiment (Gibson assembly without primer dimer) for each new
836 batch of linearized pPT2 vector.

837
838 **2 | Sequence validation**

- 839 • Due to the high efficiency/specificity of Gibson assembly, colony PCR is not required.
840 • Validate the resulting vector by sequencing with pJET1.2fwd or pJET1.2rev.

841
842 **3) *C. elegans* transformation**

843 Usually, sgRNA vectors are injected at 50 ng/ μ L.

844

845 Materials and Methods

846 pPT2 sequence file

847 The annotated sequence file for the pPT2 vector can be downloaded as a Genbank
848 format (readable in ApE and benchling.com) at the following link:

849 <http://www.excitingworms.eu/resources/pPT2.gb>

850 Homemade Gibson Assembly Reagents

851 Based on *Methods in Enzymology, Volume 498*

852 *CHAPTER FIFTEEN part 5 :Enzymatic Assembly of Overlapping DNA Fragments* (Daniel G. Gibson)

853

854 **2 M MgCl₂** Dilute 10.16 g MgCl₂ H₂O for a final volume of 25 mL.

855

856 **5X ISO Buffer, 2 mL (store at -20°C)**

857	Tris-HCl pH=7,5 1M	1 mL (T2319-1L)
858	MgCl ₂ 2 M	50 µL
859	dGTP 100 mM	20 µL
860	dATP 100 mM	20 µL
861	dTTP 100 mM	20 µL
862	dCTP 100 mM	20 µL
863	DTT 1 M	100 µL (DL-Dithiothreitol ref : 43816-10mL)
864	NAD ⁺ 50 mM	200 µL (NEB: B9007S)
865	PEG8000	0.5 g (VWR: RC-077)
866	H ₂ O	add up to 2 mL (mol. bio. grade W4502-1L)

867 • Prepare 320 µL aliquots and store at -20°C.

868

869 **Gibson Master Mix, 1.2 mL (store at -20°C)**

870 For the assembly of DNA molecules with overlaps of 20-80 bp.

871	5X ISO buffer	320 µL
872	T5 Exonuclease (10 U/µL)	0.64 µL (NEB: M0363S)
873	Phusion (2 U/µL)	20 µL
874	Taq Ligase (40 U/µL)	160 µL (NEB: M0208L)
875	H ₂ O	700 µL

876 Note: For overlaps that are larger than 80 bp, 3.2 µL exonuclease is used in this mix.

877 • Separate into 50 µL aliquots. Store at -20°C. The enzyme remains active after 10
878 cycles of freeze-thaw.

879

880 **Sequencing Primers**

881 pJET1.2fwd 5'-cgactcactataggagagcggc-3'

882 pJET1.2rev 5'-aagaacatcgatttccatggcag-3'

883

884

885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931

[Alternative protocol used for primer dimer assembly into pPT2]

III) Building the sgRNA vector

- The protospacer sequence is incorporated into the pPT2 vector as follows.

1 | Linearize pPT2 using the *PmeI* and *SexAI* restriction enzymes.

2 | Purify the linearized pPT2 vector using your method of choice (we use Qiagen Gel Purification).

3 | **Hybridize oligonucleotides** (using a thermocycler)

- Add 1 μL of each oligonucleotide (at 100 μM) to 18 μL of water.
- Run the program below on a thermal cycler to anneal primers.
- Add 30 μL of water to the resulting sample.

95°C	10 min
95°C to 85°C	[-2.0 °C/s]
85°C	1 min
85°C to 75°C	[-0.3°C/s]
75°C	1 min
75°C to 65°C	[-0.3°C/s]
65°C	1 min
65°C to 55°C	[-0.3°C/s]
55°C	1 min
55°C to 45°C	[-0.3°C/s]
45°C	1 min
45°C to 35°C	[-0.3°C/s]
35°C	1 min
35°C to 25°C	[-0.3°C/s]
25°C	1 min
4°C	Hold.

4 | Gibson assembly

- Thaw an aliquot of Gibson Master Mix and keep on ice.
- Mix 100 ng of linearized pPT2 vector with 1 μL of hybridized oligonucleotides and add water up to 5 μL if necessary.
- Add 15 μL of Gibson Master Mix to the DNA mix.
- Incubate at 50°C for 15 to 60 minutes (60 minutes is optimum).
- Transform 5 μL of this reaction, and grow on LB+Ampicilin plates.
- Perform a control experiment (Gibson assembly without primer dimer) for each new batch of linearized pPT2 vector.

5 | Sequence validation

- Due to the high efficiency/specificity of Gibson assembly, colony PCR is not required.
- Validate the resulting vector by sequencing with pJET1.2fwd or pJET1.2rev.

5) *C. elegans* transformation

Usually, sgRNA vectors are injected at 50 ng/ μL .